CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Appraise published and emerging research findings and current guideline recommendations on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and appropriately counsel patients about the potential benefits of systemic therapy.
  • Evaluate the research supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and present appropriate nonresearch treatment options to patients.
  • Explore available data with treatment intensification using cytotoxic therapy, secondary hormonal therapy or combinations of both for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of therapies for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess available research with PARP inhibitors as monotherapy for patients with mCRPC harboring a homologous recombination repair (HRR) gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
  • Understand the rationale for, available data with and ongoing research evaluating PARP inhibitors with androgen receptor-targeted therapy, and consider the potential role of these novel regimens in therapy for patients both with and without HRR gene mutations.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AUA2023/Prostate/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Himisha Beltran, MD
  Associate Professor of Medicine
  Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology
  Director of Translational Research, Medical Oncology
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Curie Therapeutics, Daiichi Sankyo Inc, Foundation Medicine, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Oncorus, Pfizer Inc, Sanofi; Contracted Research: Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo Inc, Novartis; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Stephen J Freedland, MD
  Staff Physician, Durham VA Medical Center
  Durham, North Carolina
  Professor of Urology
  Warschaw, Robertson, Law Families Chair in Prostate Cancer
  Director, Center for Integrated Research on Cancer and Lifestyle (CIRCL)
  Associate Director for Education and Training
  Samuel Oschin Comprehensive Cancer Institute
  Cedars-Sinai Medical Center
  Los Angeles, California
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Myovant Sciences, Pfizer Inc, Sanofi; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Sanofi.
  
  Fred Saad, MD
  Professor and Chief of Urology
  Director of GU Oncology
  Raymond Garneau Chair in Prostate Cancer
  University of Montreal Hospital Center (CHUM)
  Director, Prostate Cancer Research
  Montreal Cancer Institute/CRCHUM
  Montréal, Québec, Canada
  
  Consultant: AbbVie Inc, Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Tolmar; Grant/Research Support (Institution): Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Exelixis Inc, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Sanofi.
  
  Neal D Shore, MD
  Director, CPI
  Carolina Urologic Research Center
  Chief Medical Officer, Surgery/Urology
  GenesisCare
  Medical Director, CUSP: Clinical Research Consortium
  Myrtle Beach, South Carolina
  
  Consulting Agreements: AbbVie Inc, AIkido Pharma Inc, Alessa Therapeutics, Amgen Inc, Arquer Diagnostics, Asieris Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol Myers Squibb, CG Oncology, Clarity Pharmaceuticals, Clovis Oncology, Dendreon Pharmaceuticals Inc, Exact Imaging, Exact Sciences Corporation, FerGene, Ferring Pharmaceuticals, FIZE Medical, Foundation Medicine, Genentech, a member of the Roche Group, GenesisCare, Guardant Health, ImmunityBio, Incyte Corporation, Invitae, Janssen Biotech Inc, Lantheus, Lilly, MDxHealth, Merck, Minomic, Myovant Sciences, Myriad Genetic Laboratories Inc, NGM Biopharmaceuticals, Nonagen Bioscience, Novartis, Nymox Pharmaceutical Corporation, Pacific Edge, Pfizer Inc, Photocure, PlatformQ, ProFound Therapeutics, Promaxo, Propella Therapeutics Inc, Protara Therapeutics, Sanofi, Sesen Bio, Specialty Networks, Telix Pharmaceuticals Limited, Tolmar, UroGen Pharma, Vaxiion Therapeutics, Vessi Medical; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Candel Therapeutics, CG Oncology, Dendreon Pharmaceuticals Inc, DisperSol Technologies LLC, Eric Pharmaceuticals, Exact Imaging, Exelixis Inc, FKD Therapeutics Oy, Forma Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Janssen Biotech Inc, Jiangsu Yahong Meditech, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, Merck Sharp & Dohme LLC, MT Group, Myovant Sciences, Novartis, OncoCellMDx, Pacific Edge, Palette Life Sciences, Pfizer Inc, Plexxikon Inc, POINT Biopharma, Propella Therapeutics Inc, RhoVac ApS, Seagen Inc, STEBA Biotech NV, Theralase Technologies Inc, UroGen Pharma, Urotronic, US Biotest Inc, Vaxiion Therapeutics, Veru Inc, Zenflow.
  
  MODERATOR
  Matthew R Smith, MD, PhD
  Claire and John Bertucci Endowed Chair in Genitourinary Cancers
  Professor of Medicine
  Harvard Medical School
  Director, Genitourinary Malignancies Program
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research (to Institution): Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, and Merck.
  
  Release date: May 2023
  Expiration date: May 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.